Overview

  • Product name
    Human GLP1 (7-36) ELISA Kit, Fluorescent
  • Detection method
    Fluorescent
  • Precision
    Intra-assay
    Sample n Mean SD CV%
    human serum 8 7%
    Inter-assay
    Sample n Mean SD CV%
    human serum 3 9%
  • Sample type
    Cell culture supernatant, Serum, Heparin Plasma, Citrate Plasma
  • Assay type
    Sandwich (quantitative)
  • Sensitivity
    12 pg/ml
  • Range
    14.6 pg/ml - 1000 pg/ml
  • Recovery

    Sample specific recovery
    Sample type Average % Range
    Cell culture supernatant 99 93% - 102%
    Serum 109 105% - 112%
    Heparin Plasma 110 104% - 112%
    Citrate Plasma 115 107% - 123%

  • Assay time
    1h 30m
  • Assay duration
    One step assay
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Sheep, Rabbit, Horse, Cow, Pig
  • Product overview

    GLP-1 (7-36) in vitro CatchPoint SimpleStep ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of GLP-1 (7-36) protein in human serum, plasma, and cell culture supernatants.


    This CatchPoint SimpleStep ELISA kit has been optimized for Molecular Devices Microplate Readers. Click here for a list of recommended Microplate Readers.
    If using a Molecular Devices’ plate reader supported by SoftMax® Pro software, a preconfigured protocol for these CatchPoint SimpleStep ELISA Kits is available with all the protocol and analysis settings at www.softmaxpro.org.


    The CatchPoint SimpleStep ELISA employs an affinity tag labeled capture antibody and a reporter conjugated detector antibody which immunocapture the sample analyte in solution. This entire complex (capture antibody/analyte/detector antibody) is in turn immobilized via immunoaffinity of an anti-tag antibody coating the well. To perform the assay, samples or standards are added to the wells, followed by the antibody mix. After incubation, the wells are washed to remove unbound material. CatchPoint HRP Development Solution containing the Stoplight Red Substrate is added. During incubation, the substrate is catalyzed by HRP generating a fluorescent product. Signal is generated proportionally to the amount of bound analyte and the intensity is measured in a fluorescence plater reader at 530/570/590 nm Excitation/Cutoff/Emission.

  • Notes

    GLP-1 (Glucagon like peptide 1) is part of the group of incretin hormones that are secreted by the gastrointestinal tract in response to food intake to assist glucose stimulated insulin secretion and glucagon suppression. GLP-1 is a 30 aminoacid peptide cleaved from proglucagon and released by the L-cells of the distal ileum.  The intracellular precursor of GLP-1 (1-37) is cleaved to form the active peptides GLP-1 (7-37) and GLP-1 (7-36)NH2.  The active peptides bind to the GLP-1 receptor (GLP-1r) expressed in the pancreatic beta cell and are quickly metabolized by the enzyme dipeptidyl peptidase IV (DPP-IV) to form the peptide GLP-1 (9-36), which has no insulin stimulating activity.  Binding of active GLP-1 to the receptor, increases cAMP levels and potentiates insulin secretion via Protein Kinase A (PKA) and the cAMP-regulated nucleotide exchange factor (Epac2). GLP-1 and its receptor are also suggested to play a role in the central nervous systems as mediators of satiety.  Intracerebroventricular GLP-1 has been shown to induce c-FOS activity in the hypothalamus and the central nucleus of the amygdala, both of which are important in the regulation of appetite. 

    The role of GLP-1 in chronic diseases is controversial. Patients with type-II diabetes as well as morbidly obese subjects have been shown to have lower secretion of post-prandial GLP-1, which improves with treatment or weight loss.  Due to the beneficial effects of active GLP-1 as well as GLP-1r agonists in metabolic diseases, GLP-1 has been proposed to be an effective therapeutic approach to lowering glycemic levels and decreasing body fat content.  Furthermore, GLP-1 has been found to be cardioprotective during acute myocardial infarction.  In contrast with the GLP-1 protective findings, circulating GLP-1 has also been found to positively correlate with serum triclycerides and high levels are significantly associated with coronary plaque burden in patients receiving coronary CT-angiography.

  • Tested applications
    Suitable for: Sandwich ELISAmore details
  • Platform
    Pre-coated microplate (12 x 8 well strips)

Properties

  • Storage instructions
    Store at +4°C. Please refer to protocols.
  • Components 1 x 96 tests
    100X Stoplight Red Substrate 1 x 120µl
    10X Human GLP1 (7-36) Capture Antibody 1 x 600µl
    10X Human GLP1 (7-36) Detector Antibody 1 x 600µl
    10X Wash Buffer PT (ab206977) 1 x 20ml
    500X Hydrogen Peroxide (H2O2, 3%) 1 x 50µl
    Antibody Diluent CPI 1 x 6ml
    Human GLP1 Lyophilized Recombinant Protein 2 vials
    Plate Seals 1 unit
    Sample Diluent NS 1 x 50ml
    SimpleStep Pre-Coated Black 96-Well Microplate 1 unit
    Stoplight Red Substrate Buffer 1 x 12ml
  • Research areas
  • Function
    Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes.
    GLP-1 is a potent stimulator of glucose-dependent insulin release. Play important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Have growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferaton. Inhibits beta cell apoptosis.
    GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability.
    Oxyntomodulin significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness.
    Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.
  • Tissue specificity
    Glucagon is secreted in the A cells of the islets of Langerhans. GLP-1, GLP-2, oxyntomodulin and glicentin are secreted from enteroendocrine cells throughout the gastrointestinal tract. GLP1 and GLP2 are also secreted in selected neurons in the brain.
  • Sequence similarities
    Belongs to the glucagon family.
  • Post-translational
    modifications
    Proglucagon is post-translationally processed in a tissue-specific manner in pancreatic A cells and intestinal L cells. In pancreatic A cells, the major bioactive hormone is glucagon cleaved by PCSK2/PC2. In the intestinal L cells PCSK1/PC1 liberates GLP-1, GLP-2, glicentin and oxyntomodulin. GLP-1 is further N-terminally truncated by post-translational processing in the intestinal L cells resulting in GLP-1(7-37) GLP-1-(7-36)amide. The C-terminal amidation is neither important for the metabolism of GLP-1 nor for its effects on the endocrine pancreas.
  • Cellular localization
    Secreted.
  • Information by UniProt
  • Alternative names
    • GCG
    • glicentin-related polypeptide
    • GLP-1
    • GLP-1(7-36)
    • GLP-1(7-37)
    • GLP-2
    • GLP1
    • GLP1, included
    • GLP2
    • GLP2, included
    • GLUC_HUMAN
    • Glucagon
    • Glucagon like peptide 1
    • glucagon-like peptide 1
    • Glucagon-like peptide 1, included
    • Glucagon-like peptide 2
    • Glucagon-like peptide 2, included
    • GRPP
    • OXM
    • OXY
    • preproglucagon
    see all
  • Database links

Applications

Our Abpromise guarantee covers the use of ab229413 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Sandwich ELISA Use at an assay dependent concentration.

Images

  • ELISA Protocol Summary
  • Example of human GLP-1 (7-36) standard curve in Sample Diluent NS. The GLP-1 (7-36) standard curve was prepared as described in Section 10.

  • Serum of each donor was diluted 1:10 using sample diluent NS. The mean levels of GLP-1, after adjusting for dilution factor, were found at 433.5 pg/mL with a standard deviation of 277 pg/mL.

Protocols

References

ab229413 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab229413.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up